INTEGRAMED AMERICA INC
10-Q/A, 1996-11-14
OFFICES & CLINICS OF DOCTORS OF MEDICINE
Previous: INTEGRAMED AMERICA INC, 10-Q, 1996-11-14
Next: RT INDUSTRIES INC, 10QSB, 1996-11-14





================================================================================
                                UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
  
                                
                                   FORM 10-Q/A
                                Amendment No. 1
         
                          
              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 1996

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                           Commission File No. 0-20260
                           Commission File No. 1-11440

                            INTEGRAMED AMERICA, INC.
             (Exact name of Registrant as specified in its charter)


                                    Delaware
         (State or other jurisdiction of incorporation or organization)


                             One Manhattanville Road
                               Purchase, New York
                    (Address of principal executive offices)
                                   06-1150326
                      (I.R.S. employer identification no.)



                                      10577
                                   (Zip code)


                                 (914) 253-8000
              (Registrant's telephone number, including area code)


         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [  ]

         The aggregate number of shares of the Registrant's  Common Stock,  $.01
par value, outstanding on November 7, 1996 was 9,226,807.

================================================================================

<PAGE>


                            INTEGRAMED AMERICA, INC.
                                   FORM 10-Q/A

                                TABLE OF CONTENTS

                                                                          PAGE

PART I  -        FINANCIAL INFORMATION

    Item 1.      Financial Statements

                   Consolidated  Balance  Sheet at  September  30, 1996
                   (unaudited) and December 31, 1995........................ 3

                   Consolidated Statement of Operations for the three and
                   nine-month period ended September 30, 1996 and
                   1995 (unaudited)......................................... 4

                   Consolidated Statement of Cash Flows for the nine-month
                   period ended September 30, 1996 and 1995 (unaudited)..... 5

                   Notes to Consolidated Financial Statements (unaudited)..6-12

   

SIGNATURES       ............................................................13


                                        2

<PAGE>



PART I  -  FINANCIAL INFORMATION

    Item 1.      Consolidated Financial Statements
<TABLE>

                            INTEGRAMED AMERICA, INC.
                           CONSOLIDATED BALANCE SHEET
                           (all dollars in thousands)
<CAPTION>

                                     ASSETS
                                                                                      September 30, December 31,
                                                                                          1996          1995
                                                                                         -------      -------
                                                                                       (unaudited)
Current assets:
<S>                                                                                     <C>            <C>   
  Cash and cash equivalents ..........................................................   $ 4,806      $ 7,883
  Short term investments..............................................................     2,000        1,500
  Patient accounts receivable, less allowance for doubtful accounts of $114 and $64
    in 1996 and 1995, respectively....................................................     2,451        1,271
  Management fees receivable..........................................................     1,098        1,125
  Research fees receivable............................................................       223          -
  Other current assets ...............................................................       621          508
  Controlled assets of Medical Providers- (see Note 2):
      Cash............................................................................       250          296
      Accounts receivable, less allowance for doubtful accounts of $126 and $25 in
         1996 and 1995, respectively..................................................       859        1,449
      Other current assets ...........................................................        19           14
                                                                                         -------      -------
         Total controlled assets of Medical Providers.................................     1,128        1,759
         Total current assets.........................................................    12,327       14,046
                                                                                         -------      -------
    Fixed assets, net ................................................................     2,940        2,266
    Intangible assets, net............................................................     5,576        1,711
    Other assets......................................................................       215          248
                                                                                         -------      -------
         Total assets.................................................................   $21,058      $18,271
                                                                                         =======      =======

                      LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
  Accounts payable....................................................................   $   524      $   181
  Accrued liabilities.................................................................     1,310        1,307
  Due to Medical Providers-(see Note 2)...............................................       678          606
  Dividends accrued on Preferred Stock................................................       298          946
  Current portion of exclusive management rights obligation...........................       222          297
  Current portion of long-term debt...................................................       409          274
  Patient deposits ...................................................................       429          411
                                                                                         -------      -------
         Total current liabilities....................................................     3,870        4,022
                                                                                         -------      -------
Exclusive management rights obligation................................................     1,252          978
Long-term debt .......................................................................       631          340
Commitments and contingencies- (see Note 5)...........................................       -           -
Shareholders' equity - (see Note 3)
  Preferred Stock, $1.00 par value -
    3,165,644 and 3,785,378 shares  authorized in 1996 and 1995,  respectively -
    2,500,000 undesignated;  665,644 and 1,285,378 shares designated as Series A
    Cumulative Convertible in 1996 and 1995, respectively,  of which 165,644 and
    785,378
    shares were issued and outstanding in 1996 and 1995, respectively.................       166          785
  Common Stock, $.01 par value - 25,000,000 shares authorized; 9,218,311 and
    6,086,910  shares issued and outstanding in 1996 and 1995, respectively...........        92           61
  Capital in excess of par ...........................................................    35,428       31,785
  Accumulated deficit ................................................................   (20,381)     (19,700)
                                                                                         -------      -------
         Total shareholders' equity ..................................................    15,305       12,931
                                                                                         -------      -------
         Total liabilities and shareholders' equity...................................   $21,058      $18,271
                                                                                         =======      =======
</TABLE>
      See  accompanying  notes  to the  consolidated financial statements.

                                        3

<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENT OF OPERATIONS
              (all amounts in thousands, except per share amounts)

<CAPTION>

                                                                         For the                      For the
                                                                   three-month period             nine-month period
                                                                   ended September 30,           ended September 30,
                                                                   1996           1995            1996          1995
                                                                  ------         ------         -------        -------
                                                                       (unaudited)                    (unaudited)

<S>                                                               <C>            <C>            <C>            <C>    
Revenues, net (see Note 2)................................        $5,016         $4,088         $14,004        $12,508
Medical Provider retainage (see Note 2)...................           761            656           2,264          2,374
                                                                  ------         ------         -------        -------
Revenues after Medical Provider retainage (see Note 2)....         4,255          3,432          11,740         10,134
Costs of services rendered ...............................         3,678          2,433           9,228          7,438
                                                                  ------         ------         -------        -------
Network sites' contribution ..............................           577            999           2,512          2,696
                                                                  ------         ------         -------        -------
General and administrative expenses ......................         1,153            976           2,969          2,770
Research and development..................................            94             92             222            204
Amortization of intangible assets.........................           102             24             193             37
Interest income...........................................          (108)          (148)           (331)          (475)
Interest expense..........................................            11              5              26             17
                                                                  ------         ------         -------        -------
Total other expenses......................................         1,252            949           3,079          2,553
                                                                  ------         ------         -------        -------
(Loss) income before income taxes.........................          (675)            50            (567)           143
Provision for income and capital  taxes...................            18             38             114            125
                                                                  ------         ------         -------        -------  
Net (loss) income.........................................          (693)            12            (681)            18
Less: Dividends accrued on Preferred Stock................            33            111              99            442
                                                                  ------         ------         -------        -------
Net loss applicable to Common Stock
   before consideration for induced
   conversion of Preferred Stock..........................        $ (726)        $  (99)        $  (780)       $  (424)
                                                                  ======         ======         =======        =======
Net loss per share of Common Stock
   before consideration for induced
   conversion of Preferred Stock..........................        $(0.08)        $(0.02)        $ (0.11)       $ (0.07)
                                                                  ======         ======         =======        =======
Net loss per share of Common Stock (see Note 3) ..........        $(0.46)        $(0.02)        $ (0.58)       $ (0.07)
                                                                  ======         ======         =======        =======
Weighted average number of shares of
   Common Stock outstanding ..............................         8,795          6,087           7,056          6,087
                                                                  ======         ======         =======        =======
</TABLE>

  See  accompanying  notes  to the  consolidated financial statements.

                                        4

<PAGE>

<TABLE>



                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                           (all amounts in thousands)
<CAPTION>

                                                                                           For the
                                                                                     nine-month period
                                                                                    ended September 30,
                                                                                     1996         1995
                                                                                    ------       ------
                                                                                        (unaudited)
<S>                                                                                <C>         <C> 
Cash flows from operating activities:
  Net (loss) income...........................................................     $  (681)    $    18
  Adjustments to reconcile net income to net cash used in operating activities:
   Depreciation and amortization..............................................         796         567
   Writeoff of fixed assets in 1995...........................................          -            9
    Changes in assets and liabilities net of effects from acquired  businesses--
     (Increase) decrease in assets:
        Accounts receivable...................................................      (1,094)       (443)
        Management fees receivable............................................          27        (711)
        Research fees receivable..............................................          31          -
        Other current assets..................................................        (113)       (152)
        Intangible assets.....................................................         (22)         -
        Other assets..........................................................          33          32
     Decrease (increase) in controlled assets of Medical Providers:
        Accounts receivable...................................................         590         636
        Other current assets..................................................          (5)         30
     Increase (decrease) in liabilities:
        Accounts payable......................................................         343        (586)
        Accrued liabilities...................................................        (242)        490
        Due to Medical Providers..............................................          72        (131)
        Patient deposits......................................................          18        (324)
                                                                                   -------     -------
  Net cash used in operating activities.......................................        (247)       (565)
                                                                                   -------     -------

  Cash flows (used in) provided by investing activities:
     Purchase of short-term investments.......................................        (500)         -
     Purchase of net assets of acquired businesses............................        (271)       (210)
     Payments for exclusive management rights.................................        (783)       (250)
     Purchase of fixed assets and leasehold improvements......................        (974)       (693)
     Sale of fixed assets and leasehold improvements..........................          -          651
                                                                                   -------     -------

  Net cash used in investing activities.......................................      (2,528)       (502)
                                                                                   -------     -------

  Cash flows (used in) provided by financing activities:
     Principal repayments on debt.............................................        (105)        (56)
     Principal repayments under capital lease obligations.....................        (162)       (105)
     Purchase of Convertible Preferred Stock..................................         (84)       (343)
     Preferred Stock conversion costs.........................................         (18)         -
     Proceeds from exercise of Common Stock options...........................          21          -
                                                                                   -------     -------
Net cash used in financing activities.........................................        (348)       (504)
                                                                                   -------     -------

Net decrease in cash..........................................................      (3,123)     (1,571)
Cash at beginning of period...................................................       8,179      11,694
                                                                                   -------     -------

Cash at end of period.........................................................     $ 5,056     $10,123
                                                                                   =======     =======
</TABLE>

    See  accompanying  notes  to the  consolidated financial statements.

                                        5

<PAGE>



                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1 - INTERIM RESULTS:

       The accompanying  unaudited  consolidated  financial statements have been
prepared in accordance with the instructions to Form 10-Q and,  accordingly,  do
not include all of the information and footnotes  required by generally accepted
accounting  principles  for  complete  financial  statements.  In the opinion of
management,  the accompanying unaudited interim financial statements contain all
adjustments  (consisting only of normal recurring accruals) necessary to present
fairly  the  financial  position  at  September  30,  1996,  and the  results of
operations and cash flows for the interim period  presented.  Operating  results
for the interim  period are not  necessarily  indicative  of results that may be
expected  for the year ending  December  31, 1996.  These  financial  statements
should be read in  conjunction  with the financial  statements and notes thereto
included in the Company's Annual Report on Form 10-K for the year ended December
31, 1995.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

   Revenue and cost recognition --

       The Company has two divisions:  the Reproductive  Science Center Division
(the "RSC  Division") and the newly formed Adult Women's Medical Center Division
(the "AWMC Division").  The RSC Division derives its revenues from eight Network
sites which it provides management services to, including certain clinics and/or
laboratories  which are directly owned; of these Network sites,  the Westchester
Network  site will be closed and certain of its  services  will be  consolidated
with the  Mineola,  NY  Network  site in the fourth  quarter  of 1996.  The AWMC
Division  derives its revenues from the three women's  healthcare  companies and
the 51%  controlling  interest in the  National  Menopause  Foundation  which it
acquired in June 1996 (which  combined  represent  one Network site  referred to
herein as "AWMC of Gainesville").

       Under certain  management  contracts and where the Company  directly owns
the clinic or laboratory associated with the Network site, revenues are recorded
on a net realizable basis after deducting contractual  allowances and consist of
patient fees  collected by the Company on behalf of the medical  institution  or
medical  group for ART,  infertility,  laboratory  and peri and post  menopausal
women's  healthcare  services  performed at the Network  sites and/or on its own
behalf.  Under certain of these management  contracts the Company is exclusively
liable to the Medical  Providers  for physician  compensation  and other medical
costs incurred ("Medical Provider retainage"),  regardless of the actual revenue
generated by the Medical  Provider  pursuant to its  contract  with the Company.
Such retainage is segregated from clinical  revenues and paid to or on behalf of
the Medical Provider;  any balance remaining represents the Company's management
fee. Under management  contracts where the Company is not exclusively liable for
the Medical  Provider costs,  the Company's  revenues consist of management fees
which  typically  have two  components:  1) a fixed  amount per month or a fixed
percentage of both monthly net revenues and earnings after  management fees; and
2)reimbursed cost of services.

       Revenues and related  direct costs are  recognized in the period in which
the clinical and/or laboratory  services are rendered by the Medical  Providers.
Net realization is dependent upon benefits  provided by the patient's  insurance
policy  or  agreements  between  the  Network  site and the  third-party  payor.
Payments collected from patients in advance for services are included in patient
deposits.  Management  fees under contracts where the Company is not exclusively
liable for the Medical Provider costs are recorded on a net realizable basis and
are recognized in the period in which such services are rendered by the Company.
Costs  incurred  in managing  the  Network  sites,  excluding  Medical  Provider
retainage for certain contracts, are included in "Cost of services rendered".


                                        6

<PAGE>


                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
                                   (unaudited)




       Revenues  also include  amounts  earned under  research  study  contracts
between  AWMC of  Gainesville  and  various  pharmaceutical  companies.  AWMC of
Gainesville contracts with major pharmaceutical  companies (sponsors) to perform
women's  medical care research  mainly to determine the safety and efficacy of a
medication.  Based on the  data  collected  from  studies  conducted  by AWMC of
Gainesville and other non-related  centers for major  pharmaceutical  companies,
the Food and Drug  Administration  (FDA) determines  whether a medication can be
manufactured and made available to the public.  Research revenues are recognized
pursuant to each  respective  research  contract in the period which the medical
services (as  stipulated  by the research  study  protocol)  are  performed  and
collection of such fees is considered  probable.  Net  realization  is dependent
upon final approval by the sponsor that procedures  were performed  according to
study  protocol.  Payments  collected  from sponsors in advance for services are
included in accrued  liabilities,  and costs incurred in performing the research
studies are included in "Cost of services rendered".

    Patient accounts receivable --

       Patient  accounts  receivable  represent  receivables  from  patients for
medical services  provided by the Medical  Providers.  Such amounts are recorded
net of contractual  allowances and estimated bad debts. As of September 30, 1996
and December 31, 1995,  approximately  $656,000 and $150,000,  respectively,  of
accounts  receivable were a function of Network site revenue (i.e.,  the Company
purchased the accounts receivable from the Medical Providers) and the $1,795,000
and  $1,121,000  balance,  respectively,  was a function of net  revenues of the
Company (see Note 2 -- "Revenue and Cost Recognition").

    Management fees receivable --

       Management fees receivable represent fees owed to the Company pursuant to
its management  agreements with certain Network sites (see Note 2 - "Revenue and
cost recognition").

    Research Fees Receivable --

       Research  fees  receivable  represent   receivables  from  pharmaceutical
companies  for  medical  services  provided by AWMC of  Gainesville  to patients
pursuant to protocols  stipulated  under  research study  contracts  between the
pharmaceutical companies and AWMC.

    Controlled assets of Medical Providers --

       Controlled  cash  represents  segregated cash held in the name of certain
Medical Providers;  controlled accounts receivable represent patient receivables
due to certain Medical Providers,  and controlled other current assets represent
assets owned by and held in the name of certain Medical Providers,  all of which
are  reflected on the Company's  balance  sheet due to the Company's  unilateral
control of such assets.

       At  September  30, 1996 and  December 31,  1995,  of the  $1,128,000  and
$1,759,000  controlled  assets of  Medical  Providers,  $372,000  and  $279,000,
respectively, was restricted for payment of the amounts due to Medical Providers
and the balance of $756,000 and $1,480,000 was payable to the Company.



                                        7

<PAGE>


                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
                                   (unaudited)

    Intangible Assets --

       Exclusive Management Rights, Goodwill and Other Intangible Assets

       Exclusive  management  rights,   goodwill  and  other  intangible  assets
represent  costs  incurred by the Company for the right to manage and/or acquire
certain Network sites and are valued at cost less accumulated amortization.

       Trademarks

       Trademarks  represent  trademarks,  service marks,  trade names and logos
purchased by the Company and are valued at cost less accumulated amortization.

       Amortization and Recoverability

       The  Company   periodically  reviews  its  intangible  assets  to  assess
recoverability and impairments would be recognized in the consolidated statement
of  operations  if a permanent  impairment  were  determined  to have  occurred.
Recoverability  of  intangibles  is determined  based on  undiscounted  expected
earnings  from  the  related  business  unit  or  activity  over  the  remaining
amortization period.  Exclusive management rights are amortized over the term of
the  respective  management  agreement,  usually ten years.  Goodwill  and other
intangibles  are  amortized  over  periods  ranging  from three to forty  years.
Trademarks are amortized over seven years.

    Minority Interest --

       Minority  interest  represents a 49%  interest in the National  Menopause
Foundation  held by the original  owner,  now a significant  shareholder  of the
Company.  The Company  acquired its 51% interest in this entity in June 1996. At
September 30, 1996, the minority interest is included in accrued  liabilities in
the consolidated balance sheet.

NOTE 3 - SHAREHOLDERS' EQUITY:

       On June 6, 1996, the Company made a new conversion offer (the "Offer") to
the holders ("Preferred  Stockholders") of the 773,878 outstanding shares of the
Company's Series A Convertible  Preferred Stock ("Preferred  Stock").  Under the
Offer, Preferred Stockholders received four shares of the Company's Common Stock
upon  conversion of a share of Convertible  Preferred Stock subject to the terms
and  conditions  set forth in the Offer.  The  Offering was  conditioned  upon a
minimum of 400,000 shares of Preferred Stock being  tendered;  provided that the
Company reserved the right to accept fewer shares.  Upon expiration of the Offer
on July 17, 1996, the Company accepted for conversion  608,234 shares,  or 78.6%
of the Convertible  Preferred  Stock  outstanding,  constituting  all the shares
validly  tendered.  Following the  transaction,  there were 9,198,375  shares of
IntegraMed  America's Common Stock outstanding and 165,644 shares of Convertible
Preferred Stock outstanding.

        The pro-forma  effect of this change,  as if the conversion  occurred on
January 1, 1996,  would have resulted in a reduction in the net loss  applicable
to Common  Stockholders  from  $(0.11)  per share to  $(0.09)  per share for the
nine-month period ended September 30, 1996. The pro-forma effect of this change,
as if the  conversion  occurred  on January 1, 1995,  would have  resulted  in a
reduction in the net loss  applicable  to Common  Stockholders  from $(0.07) per
share to $(0.01) per share for the nine-month  period ended  September 30, 1995.
The pro forma loss per share  calculations  give effect to the 2,432,936  Common
Shares  which  were  issued in the  conversion  and the  elimination  of accrued
dividends  related to the converted  Preferred Shares of approximately  $243,000
for both 1996 and 1995,  respectively.  However,  the pro forma information does
not give effect to the inducement discussed in the following paragraph.


                                        8

<PAGE>


                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
                                   (unaudited)

        Under the Offer,  Preferred  Stockholders received four shares of Common
Stock for each share of Preferred  Stock  converted.  This Offer  represented an
increase from the original terms of the Preferred  Stock which provided for 1.45
shares of Common Stock for each share of Preferred  Stock (after  adjustment for
the failure of the Company to pay eight  dividends and after  adjustment for the
issuance of Common Stock pursuant to its  acquisition  of AWMC of  Gainesville).
Since the Company issued an additional  1,550,997  shares of Common Stock in the
conversion  offer  compared to the shares that would have been issued  under the
original terms of the Preferred Stock,  the Company was required,  pursuant to a
recently  enacted  accounting  pronouncement,  to deduct the fair value of these
additional shares of approximately  $4,265,000 from earnings available to Common
Stockholders. This non-cash charge, partially offset by the reversal of $973,000
accrued  dividends  attributable to the conversion,  resulted in the increase in
net  loss per  share  by  approximately  $(.38)  and  $(.47)  in the  three  and
nine-month period ended September 30, 1996,  respectively.  While this charge is
intended  to show the cost of the  inducement  to the  owners  of the  Company's
Common  Stock  immediately  before the  conversion  offer,  management  does not
believe that it accurately  reflects the impact of the  conversion  offer on the
Company's  Common  Stockholders.  As a result  of the  conversion,  the  Company
reversed $973,000 in accrued dividends from its balance sheet and the conversion
will save the Company from accruing annual dividends of $486,000 and the need to
include these dividends in earnings per share  calculations.  The conversion has
also eliminated a $6.1 million  liquidation  preference related to the shares of
Preferred Stock converted.

       As of September 30, 1996,  dividend  payments of $298,000 were in arrears
as a result of the  Company's  Board of Directors  suspending  nine  consecutive
quarterly dividend payments on the Preferred Stock.

NOTE 4 - ACQUISITIONS

       The transactions detailed below were accounted for by the purchase method
and the purchase price has been allocated to the assets acquired and liabilities
assumed  based upon the  estimated  fair value at the date of  acquisition.  The
unaudited  consolidated  financial  statements  include  the  results  of  these
transactions from their respective dates of acquisition.

       On June 7, 1996, the Company entered into an Agreement and Plan of Merger
(the "Agreement")  pursuant to which INMD Acquisition Corp.  ("IAC"),  a Florida
corporation  and  wholly-owned  subsidiary  of the Company,  acquired all of the
outstanding  stock of the following  three  related  Florida  corporations:  The
Climacteric Clinic, Inc. ("CCI"),  Midlife Centers of America, Inc. ("MCA"), and
Women's  Research  Centers,  Inc.  ("WRC"),  America  (collectively  "the Merger
Companies"),  and  51% of  the  outstanding  stock  of  the  National  Menopause
Foundation,  Inc. ("NMF"),  also a related Florida corporation.  Pursuant to the
Agreement,  the Merger  Companies  were merged with and into IAC, the  surviving
corporation in the Merger, which will continue its corporate existence under the
laws of the State of Florida under the name Adult Women's Medical  Center,  Inc.
("AWMC").  In exchange for the shares of the Merger Companies,  the Company paid
cash in an  aggregate  amount of $350,000  and issued  666,666  shares of Common
Stock which had a market value of $2.5  million.  In exchange for the 51% of the
outstanding  stock of NMF,  the  Company  paid  cash in an  aggregate  amount of
$50,000 and issued a note in an amount of $600,000,  which is payable in sixteen
quarterly  installments  of  $37,500  beginning  September  1, 1996 with  simple
interest at a rate of 4%.

       The aggregate  purchase  price of the Merger  Companies of $2,850,000 was
allocated as follows to assets  acquired and  liabilities  assumed:  $338,000 to
current  assets,  $99,000 to fixed assets,  $214,000 to intangible  assets which
will be amortized  over a three-year  period,  $235,000 to accrued  liabilities,
$97,000  to debt and the  balance  of  $2,531,000  to  goodwill,  which  will be
amortized  over a forty-year  period.  The  aggregate  purchase  price of NMF of
$650,000 was allocated as follows:  $2,000 to current  assets,  $30,000 to fixed
assets,  $10,000 to current  liabilities  and the $628,000  balance to goodwill,
which will be amortized over a forty-year period.

                                        9

<PAGE>

                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
                                   (unaudited)

       On May 15, 1996,  the Company  entered into an asset  purchase and a long
term management  agreement with W.F. Howard,  M.D., P.A. near Dallas, Texas (the
"Reproductive  Science  Center ("RSC") of Dallas"),  a provider of  conventional
infertility  and  assisted  reproductive   technology  services.  The  aggregate
purchase price was approximately  $701,500 of which  approximately  $244,000 was
paid at  closing  and the  Company  issued a  promissory  note for the  $457,500
balance  which is payable as follows:  $100,000 on the last  business day of May
1997 and 1998,  and $36,786 on the last business day of May in each of the seven
years thereafter,  thru May 2005. The aggregate  purchase price was allocated to
fixed  assets in the amount of $144,000 and the balance of $557,500 to exclusive
management  rights,  which  will be  amortized  over  the ten  year  term of the
agreement.

       The  following  unaudited  pro  forma  results  of  operations  have been
prepared by  management  based on the  unaudited  financial  information  of the
Merger  Companies,  NMF and the RSC of Dallas  adjusted  where  necessary,  with
respect  to  pre-acquisition  periods,  to the basis of  accounting  used in the
historical  financial  statements  of  the  Company.  Such  adjustments  include
modifying  the  unaudited  results  to  reflect  operations  as if  the  related
management  agreements  had been  consummated  on  January  1,  1996  and  1995,
respectively.  Additional  general  corporate  expenses  which  would  have been
required to support the  operations of the new Network sites are not included in
the pro forma results.  The unaudited pro forma results may not be indicative of
the results that would have occurred if the acquisition and management agreement
had been in effect  on the  dates  indicated  or which  may be  obtained  in the
future.

                                                          For the
                                                      nine-month period
                                                     ended September 30,
                                                      1996          1995
                                                     ------        ------
                                                         (unaudited)
   

Revenues, net.................................... $16,120,000   $15,126,000
                                                                -----------

(Loss) income before income taxes (1)............ $  (966,000)  $    30,000
                                                                -----------

Net (loss) applicable to Common Stock
(includes  $99,000 and $442,000  dividends
accrued on Preferred  Stock for the nine-month
period ended  September 30, 1996 and 1995,
respectively) before consideration for induced
conversion of Preferred Stock.................... $(1,179,000)  $  (605,000)
                                                                ----------- 

Net (loss) per share of Common Stock before
consideration for induced conversion of
Preferred Stock.................................. $     (0.16)  $     (0.09)
                                                                ----------- 
    

(1)  Income (loss) before income taxes include $348,000 and $192,000 of goodwill
     and   exclusive   management   rights   amortization   in  1996  and  1995,
     respectively.


NOTE 5 - COMMITMENTS AND CONTINGENCIES:

    Reliance on Third Party Vendors --

       The Network sites are dependent on three third-party  vendors that supply
patient medication.  Should any of these vendors experience a supply shortage of
medication,  it may have an  adverse  impact on the  operations  of the  Network
sites.  Currently,  the  Network  sites have not  experienced  any such  adverse
impacts.



                                       10

<PAGE>


                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
                                   (unaudited)

    Commitments to Medical Providers --

       Under certain management  contracts , the Company is obligated to perform
the  following:  (i) advance  funds to the Network  site to  guarantee a minimum
physician  draw and/or to provide to the Network site new services,  utilize new
technologies, fund projects, etc. ; and (ii) on or before the fifteenth business
day of each month  purchase  the net  accounts  receivable  of the Network  site
arising  during the  previous  month and to transfer or pay to the Network  site
such amount of funds equal to the net accounts  receivable less any amounts owed
to the Company for  management  fees and/or  advances.  Any  advances  are to be
repaid  monthly  and  interest  expense,  computed at the prime rate used by the
Company's primary bank in effect at the time of the advance,  will be charged by
the  Company for funds  advanced.  Advances  due to the Company are  included in
"management  fees  receivable" and net receivables  purchased by the Company are
included in "patient  accounts  receivable" in the balance sheet as of September
30, 1996 and December 31, 1995, respectively.

    Commitments to the National Menopause Foundation --

       In connection with its acquisition of 51% of the outstanding stock of the
National  Menopause  Foundation  ("NMF") in June 1996,  the Company will provide
funding to and for the  development of NMF on an as-needed basis during the four
year period  commencing  June 6, 1996 in amounts  not to exceed  $500,000 in the
aggregate.

    Litigation -

       On September 5, 1996,  the plaintiff in Bernstein v. IVF America,  et.al.
withdrew his appeal of the Delaware Court of Chancery's earlier decision denying
the  plaintiff's  claim that  Preferred  Stockholders  were entitled to expanded
anti-dilution rights as a result of the Company's November 1994 Conversion Offer
with respect to the Preferred Stock. As a result of the plaintiff's appeal being
withdrawn, the case has been dismissed.

       The  plaintiffs'  application  for class  certification  in Karlin v. IVF
America,  Inc. et al, filed in Supreme Court,  Westchester County, New York, has
been denied by the Court.  The Court ruled that the potential  class of patients
treated at the IVF America  Program at United Hospital did not meet the criteria
for class action  status as required by New York law. In  particular,  the Court
reached this conclusion  because,  "individualized and varied issues arising out
of the particular physician-patient relationship, more aligned with the issue of
lack of informed consent,  tend to predominate." While plaintiffs have appealed,
the Company is pleased by this decision, sustaining the individualized nature of
treatment at IVF America  Network  sites,  and intends to defend  vigorously the
Court's ruling.

NOTE 6 - RELATED PARTY TRANSACTION

       Under the AWMC of Gainesville  acquisition agreement,  Morris Notelovitz,
M.D., Ph.D.  ("Physician"),  the founder of the Gainesville entities acquired by
the Company,  became a member of the Company's Board of Directors,  and, under a
long term employment  agreement,  the Physician will serve as Vice President for
Medical Affairs and Medical Director of the Division. The Company simultaneously
entered into an Employment  Agreement  with the Physician  pursuant to which the
Physician will provide medical services, as defined.

NOTE 7 - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH
TRANSACTIONS:

       In connection  with the Company's  acquisition  of AWMC of Gainesville in
June 1996, the Company issued 666,666 shares of Common Stock,  acquired tangible
assets  of  $469,000,  assumed  current  liabilities  of  $245,000,  and debt of
$97,000,  and acquired $214,000 of intangible assets and $3,159,000 of goodwill.
In connection with this  transaction,  the Company also issued a note payable in
the amount of $600,000 with annual interest payable at 4%.


                                       11

<PAGE>



       In May 1996,  the Company  entered into a management  agreement with W.F.
Howard, M.D., P.A. located near Dallas, Texas.  Pursuant to this agreement,  the
Company  incurred a $550,000  obligation for the exclusive  right to manage this
facility.

       Pursuant  to its  management  agreement  with the  Philadelphia  Clinical
Facilities, the Company incurred a $1 million obligation for the exclusive right
to manage these facilities and assumed capital lease obligations of $89,000.

       At  September  30,  1996  and  1995,  there  were  accrued  dividends  on
Convertible  Preferred Stock outstanding of $298,000 and $788,000,  respectively
(see Note 3).

       At September 30, 1996 and 1995 controlled  cash of Medical  Providers was
$250,000 and $629,000, respectively, which represented a decrease of $46,000 and
an increase of $140,000 for the nine-month  period ended  September 30, 1996 and
1995, respectively.

       State taxes, which primarily reflect  Massachusetts  income taxes and New
York capital taxes of $103,000 and $132,000 were paid in the  nine-month  period
ended September 30, 1996 and 1995, respectively.

       Interest paid in cash in the nine-month  period ended  September 30, 1996
and 1995 amounted to $26,000 and $17,000, respectively. Interest received in the
nine-month  period ended  September  30, 1996 and 1995  amounted to $360,000 and
$554,000, respectively.




                                       12

<PAGE>




                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                            INTEGRAMED AMERICA, INC.
                                            (Registrant)




Date:    November 14, 1996              By: /s/ Dwight P. Ryan
                                            ------------------
                                            Dwight P. Ryan
                                            Vice President and
                                            Chief Financial Officer
                                            (Principal Financial and
                                            Accounting Officer)


                                       13





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission